Hyperprogression on anti-PD-1 treatment. Is subsequent therapy feasible? A case report and review of the literature

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F23%3A10157175" target="_blank" >RIV/00098892:_____/23:10157175 - isvavai.cz</a>

Alternative codes found

RIV/61989592:15110/23:73614827

Result on the web

<a href="https://biomed.papers.upol.cz/artkey/bio-202304-0012_hyperprogression-on-anti-pd-1-treatment-is-subsequent-therapy-feasible-a-case-report-and-review-of-the-liter.php" target="_blank" >https://biomed.papers.upol.cz/artkey/bio-202304-0012_hyperprogression-on-anti-pd-1-treatment-is-subsequent-therapy-feasible-a-case-report-and-review-of-the-liter.php</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2022.025" target="_blank" >10.5507/bp.2022.025</a>

Result language

angličtina

Original language name

Hyperprogression on anti-PD-1 treatment. Is subsequent therapy feasible? A case report and review of the literature

Original language description

Background. Hyperprogressive disease (HPD) is a new phenomenon that has emerged in the immunotherapy era. HPD is defined as a rapid tumour growth with detrimental effect on the patient condition and disease course. The management and treatment following HPD is not defined. We present here the case report of patient with HPD and review of the literature on putative mechanisms of HPD and following disease management. Methods and Results. A 60-year old male patient with metastatic melanoma was indicated for systemic treatment with anti-programmed cell death (PD)-1 antibody. Rapid tumour growth and detrimental effect on the patient general condition after administration of a single dose of anti-PD-1 antibody met the criteria of HPD.The patient underwent the second line taxane-based chemotherapy with good tolerance and disease stabilization. The third line treatment with anti- cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody ipilimumab was well tolerated and resulted in partial response. Re-challenge with anti-CTLA-4 antibody was feasible, but only with a modest clinical effect. Conclusion. Prompt recognition of HPD and administration of salvage chemotherapy with taxane-based regimens may be crucial. HPD is rarely observed with ipilimumab treatment. Administration of ipilimumab as well as an ipilimumab re-challenge are feasible after HPD on anti-PD-1 antibodies. Investigation of new predictive biomarkers of HPD is warranted as well as new agents that potentiate the immune response in patients affected with this insidious complication.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Biomedical Papers

ISSN

1213-8118

e-ISSN

1804-7521

Volume of the periodical

167

Issue of the periodical within the volume

4

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

9

Pages from-to

376-384

UT code for WoS article

000812184200001

EID of the result in the Scopus database

2-s2.0-85179837227